Evaluating the Human Immune Response to the JYNNEOS Vaccine

StatusActive, Not Recruiting
PhaseEarly Phase 1
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Study completion pushed from Dec 2026 to Oct 2027
    • Primary completion date changed from estimate of Sep 2026 to Sep 25, 2026
    • Eligibility criteria shortened, about 10 words
  2. Trial status: Recruiting to Active, Not Recruiting
    • Primary completion date: Jul 2026 to Sep 2026
    • Site details revised
    v4
  3. Primary completion date: Dec 2025 to Jul 2026
    • Study completion date: Dec 2025 to Dec 2026
    v3
  4. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Jun 2024 to Jun 10, 2024
    • Site details revised
    v2
  5. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study is designed to evaluate the magnitude and duration of the human adaptive immune response to the JYNNEOS Modified Vaccinia Ankara-Bavarian Nordic (MVA-BN) vaccine in the blood, lung mucosa, skin and bone marrow.
Trial Details
NCT Number NCT06366672
Lead Sponsor Washington University School of Medicine
Conditions
(from sponsor)		 Vaccinia, Virus Diseases
Related terms Vaccinia, Virus Diseases
Enrollment 20 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov